SavedAdd your journal

Journals / International Journal of Secondary Metabolite / 2020 / Cilt: 7 - Sayı: 3

Imidazole Antifungals: A Review of Their Action Mechanisms on Cancerous Cells

Berna KAVAKCIOĞLU YARDIMCI
Pages
139–159
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the action mechanisms of imidazole antifungals on cancerous cells and consequently, their potential for use in cancer treatment alone or in combination with conventional therapeutics were discussed in detail.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Imidazoles, together with triazoles, constitute azole sub-group of antifungal drugs which acts by inhibiting cytochrome P450-dependent enzyme, the lanosterol 14-α-demethylase.
📊
Key Findings & Data:Based on the findings up to now, although having different effects, disruption of the glycolytic pathway, blockage of Ca2+ influx and nonspecific inhibition of CYP450 enzymes can be regarded as the main ones responsible for the anti-neoplastic activities of the mentioned drugs, respectively.
💡
Conclusion & Impact:In this review, the action mechanisms of imidazole antifungals on cancerous cells and consequently, their potential for use in cancer treatment alone or in combination with conventional therapeutics were discussed in detail.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Imidazole Antifungals · Clotrimazole · Econazole

Abstract

Imidazoles, together with triazoles, constitute azole sub-group of antifungal drugs which acts by inhibiting cytochrome P450-dependent enzyme, the lanosterol 14-α-demethylase. In addition to their primary use, when it comes to additional anti-cancer function, clotrimazole, econazole and ketoconazole have come to the fore among the imidazoles. Based on the findings up to now, although having different effects, disruption of the glycolytic pathway, blockage of Ca2+ influx and nonspecific inhibition of CYP450 enzymes can be regarded as the main ones responsible for the anti-neoplastic activities of the mentioned drugs, respectively. Considering the advantages of repurposing of drugs with known pharmacology compared to new drug development studies requiring labor, time and cost, it will be extremely important and valuable to continue the clarification of the different mechanisms of these antifungals on cancerous cells and benefit from them especially to increase drug efficacy and overcome drug resistance. In this review, the action mechanisms of imidazole antifungals on cancerous cells and consequently, their potential for use in cancer treatment alone or in combination with conventional therapeutics were discussed in detail.

Özet

Imidazoles, together with triazoles, constitute azole sub-group of antifungal drugs which acts by inhibiting cytochrome P450-dependent enzyme, the lanosterol 14-α-demethylase. In addition to their primary use, when it comes to additional anti-cancer function, clotrimazole, econazole and ketoconazole have come to the fore among the imidazoles. Based on the findings up to now, although having different effects, disruption of the glycolytic pathway, blockage of Ca2+ influx and nonspecific inhibition of CYP450 enzymes can be regarded as the main ones responsible for the anti-neoplastic activities of the mentioned drugs, respectively. Considering the advantages of repurposing of drugs with known pharmacology compared to new drug development studies requiring labor, time and cost, it will be extremely important and valuable to continue the clarification of the different mechanisms of these antifungals on cancerous cells and benefit from them especially to increase drug efficacy and overcome drug resistance. In this review, the action mechanisms of imidazole antifungals on cancerous cells and consequently, their potential for use in cancer treatment alone or in combination with conventional therapeutics were discussed in detail.

🔖

Cite This Article

YARDIMCI, B. K. (2022). Imidazole Antifungals: A Review of Their Action Mechanisms on Cancerous Cells. International Journal of Secondary Metabolite, Cilt: 7 - Sayı: 3, 139–159. https://ajindex.com/articles/541646

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Almutairi, M.S., Manimaran, D., Joe, I.H., Saleh, O.A., Attia, M.I. (2015). Structural properties and biological prediction of ({[(1E)-3-(1H-Imidazol-1-yl)-1-phenylpropylidene]amino}oxy)(4-methylphenyl) methanone: An in silico approach. Symmetry, 8(1), 1. Campoy, S., Adrio, J.L. (2017). Antifungals. Biochem. Pharmacol., 133, 86-96.
  2. Sheehan, D.J., Hitchcock, C.A., Sibley, C.M. (1999). Current and emerging azole antifungal agents. Clin. Microbiol. Rev., 12(1), 40-79.
  3. Allen, D., Wilson, D., Drew, R., Perfect, J. (2015). Azole antifungals: 35 years of invasive fungal infection management. Expert Rev. Anti-infect. Ther., 13(6), 787-798.
  4. Kadavakollu, S., Stailey, C., Kunapareddy, C.S., White, S. (2014). Clotrimazole as a cancer drug: a short review. Med. Chem., 4(11), 722. Sequeira, S.O., Laia, C.A.T., Phillips, A.J.L., Cabrita, E.J., Macedo, M.F. (2017). Clotrimazole and calcium hydroxide nanoparticles: A low toxicity antifungal alternative for paper conservation. J. Cult. Herit., 24, 45-52.
  5. Spiekermann, P.H., Young, M.D. (1976). Clinical evaluation of clotrimazole: a broad-spectrum antifungal agent. Arch. Dermatol., 112(3), 350-352.
  6. Hegemann, L., Toso, S.M., Lahijani, K.L., Webster, G.F., Uitto, J. (1993). Direct interaction of antifungal azole-derivatives with calmodulin: a possible mechanism for their therapeutic activity. J. Investig. Dermatol., 100(3), 343-346.
  7. Stevens, F.C. (1983) Calmodulin: an introduction. Biochem. Cell Biol., 61(8), 906-910.
  8. Hidaka, H., Hartshorne, D.J. (1985). Calmodulin Antagonists and Cellular Physiology, Academic: New York. Arnold, H., Pette, D. (1968). Binding of glycolytic enzymes to structure proteins of the muscle. Eur. J. Biochem., 6(2), 163-171.
  9. Gots, R.E., Bessman, S.P. (1974). The functional compartmentation of mitochondrial hexokinase. Arch. Biochem. Biophys., 163(1), 7-14.
  10. Gots, R.E., Gorin, F.A., Bessman, S.P. (1972). Kinetic enhancement of bound hexokinase activity by mitochondrial respiration. Biochem. Biophys. Res. Commun., 49(5), 1249-1255.
  11. Viitanen, P.V., Geiger, P.J., Erickson-Viitanen, S., Bessman, S.P. (1984). Evidence for functional hexokinase compartmentation in rat skeletal muscle mitochondria. J. Biol. Chem., 259(15), 9679-9686.
  12. Eigenbrodt, E., Fister, P., Reinacher, M. New Perspectives on Carbohydrate Metabolism in Tumor Cells In: Regulation of Carbohydrate Metabolism, Rivka Beitner, Ed. CRC Press: Boca Raton, 1985, Vol. 2, pp. 141-79.
  13. Kottke, M., Adam, V., Riesinger, I., Bremm, G., Bosch, W., Brdiczka, D.,